Nanoviricides (NNVC) Research & Development (2010 - 2026)
Nanoviricides (NNVC) posted Research & Development of $1.3 million for Q1 2026, up 14.95% sequentially from $1.1 million in Q4 2025, and little changed YoY from $1.3 million in Q1 2025.
Nanoviricides (NNVC) Research & Development (2010 - 2026) Analysis & Trends
Nanoviricides has reported Research & Development for 17 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Research & Development changed 0.29% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 17.62% YoY) and the FY2025 annual result came in at $5.5 million, up 2.06% from the prior year.
- Research & Development improved to $1.3 million in Q1 2026 per NNVC's latest filing, from $1.1 million in the prior quarter.
- Over five years, Research & Development peaked at $1.9 million in Q3 2024 and troughed at -$3.7 million in Q2 2022.
- A 5-year average of $712818.5 and a median of $1.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development sank 332.2% in 2022, then surged 135.58% in 2024.
- Over 5 years, Research & Development stood at $1.2 million in 2022, then soared by 34.44% to $1.6 million in 2023, then slipped by 26.53% to $1.2 million in 2024, then dropped by 3.26% to $1.1 million in 2025, then rose by 14.95% to $1.3 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.3 million, $1.1 million, and $993066.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Nanoviricides | 28.31 Mn | 25.10 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 993,066.00 |
| Jun 30, 2025 | 1.18 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.93 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | 1.57 Mn |
| Sep 30, 2023 | 1.47 Mn |
| Jun 30, 2023 | -3.32 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | -3.68 Mn |
| Mar 31, 2022 | 1.26 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 2.10 Mn |
| Jun 30, 2021 | 1.58 Mn |